References
- Crowley JJ , SullivanPF, McLeodHL. Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics10(2) , 161–163 (2009).
- Guessous I , GwinnM, KhouryMJ. Genome-wide association studies in pharmacogenomics: untapped potential for translation. Genome Med.1(4) , 46 (2009).
- Roden DM , AltmanRB, BenowitzNL et al. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145(10) , 749–757 (2006).
- Motsinger-Reif AA , JorgensonE, RellingMV et al. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet. Genomics doi: 10.1097/FPC.0b013e32833d7b45 (2010) (Epub ahead of print).
- Weinshilboum R , WangL. Pharmacogenomics: bench to bedside. Nat. Rev. Drug Discov.3(9) , 739–748 (2004).
- Roses AD . Pharmacogenetics in drug discovery and development: a translational perspective. Nat. Rev. Drug Discov.7(10) , 807–817 (2008).
- Limdi NA , VeenstraDL. Expectations, validity, and reality in pharmacogenetics. J. Clin. Epidemiol.63(9) , 960–969 (2010).
- Carlquist JF , HorneBD, MuhlesteinJB et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis 22(3) , 191–197 (2006).
- Aquilante CL , LangaeeTY, LopezLM et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79(4) , 291–302 (2006).
- Rieder MJ , ReinerAP, GageBF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22) , 2285–2293 (2005).
- Cooper GM , JohnsonJA, LangaeeTY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112(4) , 1022–1027 (2008).
- Shuldiner AR , O‘ConnellJR, BlidenKP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8) , 849–857 (2009).
- Daly AK , DonaldsonPT, BhatnagarP et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet.41(7) , 816–819 (2009).
- Link E , ParishS, ArmitageJ et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med.359(8) , 789–799 (2008).
- Abe T , UnnoM, OnogawaT et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120(7) , 1689–1699 (2001).
- Trevino LR , ShimasakiN, YangW et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27(35) , 5972–5978 (2009).
- Yang JJ , ChengC, YangW et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301(4) , 393–403 (2009).
- French D , YangW, ChengC et al. Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood 113(19) , 4512–4520 (2009).
- Elia J , GlessnerJT, WangK et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat. Genet. 44(1) , 78–84 (2011).
▪ Website
- A catalog of published genome-wide association studies. www.genome.gov/gwastudies/